Chen SL, Morgan TR. The natural history of Hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47–52. https://doi.org/10.7150/ijms.3.47.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization (WHO). Interim Guidance For Country Validation of Viral Hepatitis Elimination. 2021.

Kim NG, Kullar R, Khalil H, Saab S. Meeting the WHO Hepatitis C virus elimination goal: review of treatment in paediatrics. J Viral Hepat. 2020;27:762–9. https://doi.org/10.1111/jvh.13317.

Article  PubMed  Google Scholar 

World Health Organization (WHO)- guidelines. GUIDELINES FOR THE CARE AND TREATMENT OF PERSONS DIAGNOSED WITH CHRONIC HEPATITIS C VIRUS INFECTION. 2018.

World Health Organization (WHO). Executive summary. The Selection and Use of Essential Medicines 2021 Report of the 23 rd WHO Expert Committee on the Selection and Use of Essential Medicines 2021:26.

World Health Organization (WHO). Accelerating access to hepatitis C diagnostics and treatment. Global progress report. 2020.

World Health Organization (WHO). Updated recommendations on HCV simplified service delivery and HCV diagnostics: policy brief. 2022.

World Health Organization (WHO). Executive summary - Global hepatitis report. 2017.

World Health Organization (WHO). World Health Organization. Essent List Med - World Heal Organ; 2021.

Lallemant M, Victor M, Janice L, Diana F. Clarke. Toolkit for Research and Development of Paediatric Antiretroviral Drugs and formulations. World Heal Organ. 2019;84–109.

World Health Organization (WHO). Updated recommendations on treatment of adolescents and children with chronic hcv infection: policy brief. 2022.

World Health Organization (WHO). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. vol. 53. 2021.

Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T, Daclatasvir. A review of preclinical and clinical pharmacokinetics. Clin Pharmacokinet. 2018;57:911–28. https://doi.org/10.1007/s40262-017-0624-3.

Article  PubMed  CAS  Google Scholar 

Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B polymerase inhibitor Sofosbuvir. Clin Pharmacokinet. 2015;54:677–90. https://doi.org/10.1007/s40262-015-0261-7.

Article  PubMed  CAS  Google Scholar 

Nagaty A, Helmy SHA, Abd El-Wahab EW. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt. Trans R Soc Trop Med Hyg. 2020;114:200–12. https://doi.org/10.1093/trstmh/trz079.

Article  PubMed  CAS  Google Scholar 

Gamal N, Gitto S, Andreone P. Efficacy and safety of Daclatasvir in Hepatitis C: an overview. J Clin Transl Hepatol. 2016;4:336. https://doi.org/10.14218/JCTH.2016.00038.

Article  PubMed  PubMed Central  Google Scholar 

Butt Z, Shah SMA. Daclatasvir plus sofosbuvir with or without Ribavirin in patients with chronic hepatitis c genotype 3a in Pakistani population-a real world experience. Pakistan J Med Sci. 2019;35:409–13. https://doi.org/10.12669/pjms.35.2.637.

Article  Google Scholar 

Belperio PS, Shahoumian TA, Loomis TP, Mole LA, Backus LI. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol. 2019;70:15–23. https://doi.org/10.1016/J.JHEP.2018.09.018.

Article  PubMed  CAS  Google Scholar 

Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV genotype 3-Infected patients: real-world outcomes from Pakistan. Front Pharmacol. 2020;11:1. https://doi.org/10.3389/fphar.2020.550205.

Article  CAS  Google Scholar 

Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, et al. Generic daclatasvir plus sofosbuvir, with or without Ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47:421–31. https://doi.org/10.1111/apt.14428.

Article  PubMed  CAS  Google Scholar 

Zhuang L, Li J, Zhang Y, Ji S, Li Y, Zhao Y, et al. Real-world effectiveness of direct-acting antiviral regimens against Hepatitis C Virus (HCV) Genotype 3 infection: a systematic review and Meta-analysis. Ann Hepatol. 2021;23. https://doi.org/10.1016/j.aohep.2020.09.012.

World Health Organization (WHO). Accelerating access to hepatitis C diagnostics and treatment overcoming barriers in low-and middle-income countries. Accel Access to Hepat C Diagnostics treat overcoming barriers low-and Middle. -Income Ctries. 2020;1:6–76.

Google Scholar 

Sarwar S, Tarique S, Aleem A, Khan AA. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. Eur J Gastroenterol Hepatol. 2019;31:1035–9. https://doi.org/10.1097/MEG.0000000000001376.

Article  PubMed  CAS  Google Scholar 

Wiegand J, Schiefke I, Stein K, Berg T, Kullig U, Ende K. Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders. Hamostaseologie. 2017;37:127–30. https://doi.org/10.5482/HAMO-16-05-0014.

Article  PubMed  Google Scholar 

Flower B, Hung LM, Mccabe L, Ansari MA, Le Ngoc C, Vo Thi T, et al. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study. Elife. 2023;12. https://doi.org/10.7554/eLife.81801.

El-Shabrawi MH, Abdo AM, El‐Khayat HR, Yakoot M. Shortened 8 weeks course of dual Sofosbuvir/Daclatasvir therapy in adolescent patients, with chronic Hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;66:425–7. https://doi.org/10.1097/MPG.0000000000001838.

Article  PubMed  CAS  Google Scholar 

Yakoot M, Abdo AM, Abdel-Rehim S, Helmy S. Response tailored Protocol Versus the fixed 12Weeks course of dual Sofosbuvir/Daclatasvir Treatment in Egyptian patients with chronic Hepatitis C Genotype-4 infection: a randomized, Open-label, non-inferiority trial. EBioMedicine. 2017;21:182–7. https://doi.org/10.1016/j.ebiom.2017.05.011.

Article  PubMed  PubMed Central  Google Scholar 

Chakravarti A, Chauhan MS, Dogra G, Banerjee S. Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings? Brazilian J Infect Dis. 2013;17:369–74. https://doi.org/10.1016/j.bjid.2012.10.028.

Article  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372. https://doi.org/10.1136/bmj.n71

Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database Syst Rev Implement Rep 2019:2127–33. https://doi.org/10.11124/JBISRIR-D-19-00099

García-Pérez MA. Statistical conclusion validity: some common threats and simple remedies. Front Psychol. 2012;3. https://doi.org/10.3389/fpsyg.2012.00325.

Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974–8. https://doi.org/10.1136/jech-2013-203104.

Article  PubMed  Google Scholar 

Dekkers OM, Egger M, Altman DG, Vandenbroucke JP. Distinguishing case series from cohort studies. Ann Intern Med. 2012;156:37–40. https://doi.org/10.7326/0003-4819-156-1-201201030-00006.

Article  PubMed  Google Scholar 

Barker TH, Migliavaca CB, Stein C, Colpani V, Falavigna M, Aromataris E, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21. https://doi.org/10.1186/s12874-021-01381-z.

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–34. https://doi.org/10.1136/bmj.316.7129.469.

Article  CAS  Google Scholar 

Duval S, Tweedie R. A nonparametric Trim and fill Method of Accounting for Publication Bias in Meta-Analysis. J Am Stat Assoc. 2000;95:89. https://doi.org/10.2307/2669529.

Article  Google Scholar 

Dahari H, Halfon P, Cotler SJ. Resurrection of response-guided therapy for sofosbuvir combination therapies. J Hepatol. 2016;65:462–4. https://doi.org/10.1016/j.jhep.2016.05.028.

Article  PubMed  CAS  PubMed Central  Google Scholar 

Kowdley KV, Nelson DR, Lalezari JP, Box T, Gitlin N, Poleynard G, et al. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir. Liver Int off J Int Assoc Study Liver. 2016;36:1611–8. https://doi.org/10.1111/liv.13165.

Article  CAS  Google Scholar 

The R, Foundation R. The R Project for Statistical Computing 2018. https://www.r-project.org/ (accessed October 3, 2024).

Hezode C, Leroy V, Rosa I, Roudot-Thoraval F, Pawlotsky J-M, de Ledinghen V, et al. Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus genotype 3 infection. J Hepatol. 2017;66:S299–300.

Article  Google Scholar 

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25. https://doi.org/10.1056/NEJMoa1503153.

Article  PubMed  CAS  Google Scholar 

Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–25. https://doi.org/10.1056/NEJMOA1503153/SUPPL_FILE/NEJMOA1503153_DISCLOSURES.PDF.

Article  PubMed  CAS  Google Scholar 

Rolland S, Vachon M-L. Sofosbuvir for the treatment of hepatitis C virus infection. Can Med Assoc J. 2015;187:203–4. https://doi.org/10.1503/cmaj.140151.

Article  Google Scholar 

Food US, Drug Administration (FDA). FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks. Case Med Res. 2019. https://doi.org/10.31525/cmr-1dcddeb.

Article  Google Scholar 

Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, et al. Sofosbuvir and Ledipasvir for 8 weeks for the Treatment of Chronic Hepatitis C Virus (HCV) infection in HCV-Mono